News & Events

Advancing Cancer Treatment with Enhanced Nerofe

31 Mar|

ISK is proud to announce a significant development in our ongoing commitment to cancer research and treatment. We have successfully developed and are now in the process of filing a patent for an enhanced form of Nerofe, our proprietary cancer treatment.

This advancement represents a major milestone in our mission to combat cancer. The enhanced form

Dr. Devary: Transforming “Cold Tumors” into “Hot Tumors”: Nerofe and DOX Synergy against KRAS Mutations

26 Oct|

Second FDA approved clinical trial in patients with pancreatic cancer and metastatic colorectal

18 Dec|

ISK is excited to report the official opening of its second FDA approved clinical trial in the US in patients with pancreatic cancer and metastatic colorectal cancer at Georgetown University in Washington, D.C.

IRB approval to open the trial in Georgetown University for the treatment of mtKRAS tumors from GI track

29 Nov|

Following FDA approval to open our trial at Georgetown University in Washington DC, we received final IRB approval to open the trial in Georgetown University for the treatment of mtKRAS tumors from GI track

New Nerofe Formulation for treatment of Stage 4 squamous cell lung cancer

29 Nov|

Using a new formulation of Nerofe, treating a patient with Stage 4 squamous cell lung cancer (positive for ST2), caused the complete disappearance of some tumors and a decrease in the size of other tumors. Increase in hepatic function.

New Nerofe Formulation for treatment of adenocarcinoma in the anus with metastasis in the peritoneum

29 Nov|

Using a new formulation of Nerofe on a patient (positive for ST2) with adenocarcinoma in the anus and two metastasis in the peritoneum caused the complete disappearance of tumors.

ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC

23 Oct|

ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC

Phase II update – A second patient (92 years old) had a strong reduction in blasts in the bone marrow

01 Jun|

No side effects were recorded

Update from AML human trial in Miami

04 May|

Who is entitled to enroll in the trial:
AML /Hi-Risk MDS patients with:

8 weeks of life expectancy.
clinically deteriorating.
have no more available treatments.

In cohort 1 (dose=6mg/m^2) three patients were enrolled.

The first patient was alive with this dose for 5 months.
The second patient was alive with this dose for 1.5 months.
The third

Georgetown University at Washington DC has signed a contract with ISK to run a clinical trial with patients with mtKRAS tumors

17 Feb|

The prestigious medical center Georgetown University at Washington DC has sign a contract with ISK to run a clinical trial with patients with mtKRAS pancreas and colon cancers.